조형우
#림프종 #다발골수종 #만성림프구백혈병 #원인미상암
|
학력
2014 .03 ~ 2016 .02울산대학교 의학 석사
2005 .03 ~ 2011 .02중앙대학교 의학 학사
2005 .03 ~ 2011 .02중앙대학교 의학 학사
경력
2020 .03 ~ 현재서울아산병원 종양내과 임상전임강사
2019 .05 ~ 2020 .02서울아산병원 종양내과 임상강사
2012 .03 ~ 2016 .02서울아산병원 내과 전공의
2011 .03 ~ 2012 .02서울아산병원 수련의
2019 .05 ~ 2020 .02서울아산병원 종양내과 임상강사
2012 .03 ~ 2016 .02서울아산병원 내과 전공의
2011 .03 ~ 2012 .02서울아산병원 수련의
논문
Risk Stratification Using Multivariable Fractional Polynomials in Diffuse Large B-Cell Lymphoma.
Perioperative FLOT: new standard for gastric cancer?
Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses.
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin.
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic
Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma.
Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases.
A New Prognostic Model for Multiple Myeloma Patients in the Era of Novel Agents.
Perioperative FLOT: new standard for gastric cancer?
Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses.
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin.
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic
Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma.
Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases.
A New Prognostic Model for Multiple Myeloma Patients in the Era of Novel Agents.
저서
저서 내용이 없습니다.
보도자료
보도자료 내용이 없습니다.
포스팅
Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor after failure of at least imatinib and sunitinib
Prognostic factors for residual lesion surgery following disease control with standard dose imatinib treatment in patients with advanced gastrointestinal stromal tumor
Role of resection following focal progression with standard doses of imatinib in patients with advanced gastrointestinal stromal tumor: Results of propensity score analyses
Prognostic factors in patients (pts) with advanced biliary tract cancer (BTC) treated with first-line gemcitabine plus cisplatin (GEMCIS): Retrospective analysis of 740 pts
A New Prognostic Model for Multiple Myeloma Patients in the Era of Novel Agents
Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XPID) in patients with advanced gastric cancer with peritoneal metastasis
A New Prognostic Index for Multiple Myeloma patients in the era of novel agents
Prognostic factors for residual lesion surgery following disease control with standard dose imatinib treatment in patients with advanced gastrointestinal stromal tumor
Role of resection following focal progression with standard doses of imatinib in patients with advanced gastrointestinal stromal tumor: Results of propensity score analyses
Prognostic factors in patients (pts) with advanced biliary tract cancer (BTC) treated with first-line gemcitabine plus cisplatin (GEMCIS): Retrospective analysis of 740 pts
A New Prognostic Model for Multiple Myeloma Patients in the Era of Novel Agents
Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XPID) in patients with advanced gastric cancer with peritoneal metastasis
A New Prognostic Index for Multiple Myeloma patients in the era of novel agents
영상자료
영상자료 내용이 없습니다.
발표자료
Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)
Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XPID) in patients with advanced gastric cancer with peritoneal metastasis
Phase II study of preoperative capecitabine and oxaliplatin-based intensified chemoradiotherapy with or without induction chemotherapy in patients with locally advanced rectal cancer and synchronous liver-
limited resectable metastases
Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XPID) in patients with advanced gastric cancer with peritoneal metastasis
Phase II study of preoperative capecitabine and oxaliplatin-based intensified chemoradiotherapy with or without induction chemotherapy in patients with locally advanced rectal cancer and synchronous liver-
limited resectable metastases